An Early Phase 1 interventional study of VKA and Direct Oral Anticoagulant (DOAC) in Atrial Fibrillation (AF) and Stroke (in Patients With Atrial Fibrillation), sponsored by Population Health Research Institute. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.
Sponsored by Population Health Research Institute · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Atrial Fibrillation by Population Health Research Institute — 6 open to participants now, 6 under way, 1 of them phase 3. Atrial Fibrillation · Population Health Research Institute.
Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, this one is the 16th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is the only one in phase 1, and was the 30th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →6 of the 30 studies in Atrial Fibrillation by Population Health Research Institute are open now, in 12 countries. Recruiting first, the newest first:
Population Health Research Institute · Sites in United States, Austria, Canada and 2 more countries
Ages 18+
Population Health Research Institute · Sites in Canada
Ages 18–120
Population Health Research Institute · Sites in Canada
Ages 18+
Population Health Research Institute · Sites in Canada
Ages 18+
Population Health Research Institute · Sites in United States, Argentina, Australia and 15 more countries
Ages 55+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 300 across the 24 interventional studies, 253 across the 6 observational. Of the 21 that completed or were terminated, 3 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
Population Health Research Institute is the lead sponsor of 115 studies on the registry; 26 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
3 of the studies in Atrial Fibrillation by Population Health Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011095Population Health Research InstituteDOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial | 2027-02-03 |
| NCT06486636Population Health Research InstitutePericardiotomy in Cardiac Surgery | 2027-09-01 |
| NCT05434819Population Health Research InstituteSurgical Ablation of AF Efficacy Trial | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 30 studies in Atrial Fibrillation by Population Health Research Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin.
The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke.
The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vitamin K Antagonist
Drug: VKA
Direct oral anticoagulant (locally approved)
Drug: Direct Oral Anticoagulant (DOAC)
Warfarin
Locally approved DOACs
Also known as: Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Apixaban (Eliquis)
Feasibility - Recruitment
Recruitment rate; 1 patient per month per center at 9 Canadian stroke centers
Time frame: From site activation until the end of recruitment (approximately 24 months)
Feasibility - Adherence to Assigned Medication
Proportion of participants who cross-over (i.e., vitamin K antagonist to DOAC, or DOAC to vitamin K antagonist) is \<5%
Time frame: Enrollment to final visit (average 12 months)
Feasibility - Retention
Retention of ≥95% of study participants
Time frame: At 6 months from randomization
No study locations are listed for this record.
Start is estimated for Sep 2025; primary completion for Feb 2027, 17 months later.
Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 17 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Direct Oral Anticoagulant
Population Health Research Institute →